Correlation Between Evelo Biosciences and Cyclacel Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Evelo Biosciences and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Evelo Biosciences and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Evelo Biosciences and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on Evelo Biosciences and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Evelo Biosciences with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Evelo Biosciences and Cyclacel Pharmaceuticals.

Diversification Opportunities for Evelo Biosciences and Cyclacel Pharmaceuticals

-0.65

Correlation Coefficient

Evelo Biosciences  Cyclacel Pharmaceuticals

Excellent diversification

The 3 months correlation between Evelo and Cyclacel is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Evelo Biosciences and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and Evelo Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Evelo Biosciences are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of Evelo Biosciences i.e., Evelo Biosciences and Cyclacel Pharmaceuticals go up and down completely randomly.

Pair Corralation between Evelo Biosciences and Cyclacel Pharmaceuticals

Given the investment horizon of 90 days Evelo Biosciences is expected to generate 2.29 times more return on investment than Cyclacel Pharmaceuticals. However, Evelo Biosciences is 2.29 times more volatile than Cyclacel Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Cyclacel Pharmaceuticals is currently generating about 0.02 per unit of risk. If you would invest  2,880  in Evelo Biosciences on September 15, 2024 and sell it today you would lose (2,057) from holding Evelo Biosciences or give up 71.42% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	29.27%
Values	Daily Returns

Evelo Biosciences  vs.  Cyclacel Pharmaceuticals

Evelo Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Evelo Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, Evelo Biosciences is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Preferred Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Evelo Biosciences and Cyclacel Pharmaceuticals

The main advantage of trading using opposite Evelo Biosciences and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Evelo Biosciences position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.

The idea behind Evelo Biosciences and Cyclacel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..